| Bioactivity | HVEM(14-39) is a B- and T-lymphocyte attenuator (BTLA) peptide inhibitor. HVEM (14-39) can be combined with BTLA with a KD of 0.102 μM. HVEM(14-39) enhances the activation and proliferation of T cells by regulating the expression of BTLA and HVEM in T cells, and promotes the transformation of cells into effector memory T cells. HVEM(14-39) inhibits tumor cell proliferation and promotes late apoptosis. HVEM(14-39) has immunomodulatory effects and can be used in the study of cancer[1]. |
| Sequence | Ac-Glu-Ser-Cys-Pro-Lys-Cys-Ser-Pro-Gly-Tyr-Arg-Val-Lys-Glu-Ala-Cys-Gly-Glu-Leu-Thr-Gly-Thr-Val-Cys-Glu-Pro-NH2 (Disulfide bridge:Cys3-Cys16;Cys6-Cys24) |
| Shortening | Ac-ESCPKCSPGYRVKEACGELTGTVCEP-NH2 (Disulfide bridge:Cys3-Cys16;Cys6-Cys24) |
| Formula | C115H182N32O40S4 |
| Molar Mass | 2781.13 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wojciechowicz K, et al. Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma. Biomed Pharmacother. 2024 Jun;175:116675. |